Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.

Aim. Тo determine the serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention.Materials and methods We examined 23 type 1 diabetic patient with microangyopathy and arterial hypertention, 10 type 1 diabetic patient with microangyopathy without hypertention an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liliya A. Mogylnytska, Boris N. Mankovsky
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	endothelial monocyte-activating polypeptide ii endothelial dysfunction type 1 diabetes arterial hypertension Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/f02c5b841db24e72815ed8a6e4d772b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f02c5b841db24e72815ed8a6e4d772b2
record_format	dspace
spelling	oai:doaj.org-article:f02c5b841db24e72815ed8a6e4d772b22021-11-14T09:00:20ZSerum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.2072-03512072-037810.14341/DM7674https://doaj.org/article/f02c5b841db24e72815ed8a6e4d772b22016-11-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7674https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. Тo determine the serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention.Materials and methods We examined 23 type 1 diabetic patient with microangyopathy and arterial hypertention, 10 type 1 diabetic patient with microangyopathy without hypertention and 28 control subjects. Serum levels of EMAP-II were determined by immunoenzyme assay. The data were presented as means±SD. Results. We found an increased serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention compared to control group (5,23±1,66 ng/ml and 1,25±0,76 ng/ml respectively, р<0,01), and in type 1 diabetic patients with microangyopathy and arterial hypertension compared to group without hypertension (5,23±1,66 ng/ml and 3,63±1,9 ng/ml respectively, р<0,01). Also, the level of EMAP-II correlated with key markers of carbohydrate and lipid metabolism, inverse correlated with endothelium-dependent dilatation (p<0,05).Conclusion. The revealed change of EMAP-II could reflect an endothelial dysfunction in patients with type 1 diabetes with microangyopathy and arterial hypertension. Arterial hypertension, hyperglycemia, dyslipidemia appears to be significant factor to contributing elevation of EMAP-II.Keywords: Endothelial monocyte activating polypeptide II, endothelial dysfunction, type 1 diabetes, arterial hypertension.Liliya A. MogylnytskaBoris N. MankovskyEndocrinology Research Centrearticleendothelial monocyte-activating polypeptide iiendothelial dysfunctiontype 1 diabetesarterial hypertensionNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 4, Pp 309-314 (2016)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	endothelial monocyte-activating polypeptide ii endothelial dysfunction type 1 diabetes arterial hypertension Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	endothelial monocyte-activating polypeptide ii endothelial dysfunction type 1 diabetes arterial hypertension Nutritional diseases. Deficiency diseases RC620-627 Liliya A. Mogylnytska Boris N. Mankovsky Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.
description	Aim. Тo determine the serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention.Materials and methods We examined 23 type 1 diabetic patient with microangyopathy and arterial hypertention, 10 type 1 diabetic patient with microangyopathy without hypertention and 28 control subjects. Serum levels of EMAP-II were determined by immunoenzyme assay. The data were presented as means±SD. Results. We found an increased serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention compared to control group (5,23±1,66 ng/ml and 1,25±0,76 ng/ml respectively, р<0,01), and in type 1 diabetic patients with microangyopathy and arterial hypertension compared to group without hypertension (5,23±1,66 ng/ml and 3,63±1,9 ng/ml respectively, р<0,01). Also, the level of EMAP-II correlated with key markers of carbohydrate and lipid metabolism, inverse correlated with endothelium-dependent dilatation (p<0,05).Conclusion. The revealed change of EMAP-II could reflect an endothelial dysfunction in patients with type 1 diabetes with microangyopathy and arterial hypertension. Arterial hypertension, hyperglycemia, dyslipidemia appears to be significant factor to contributing elevation of EMAP-II.Keywords: Endothelial monocyte activating polypeptide II, endothelial dysfunction, type 1 diabetes, arterial hypertension.
format	article
author	Liliya A. Mogylnytska Boris N. Mankovsky
author_facet	Liliya A. Mogylnytska Boris N. Mankovsky
author_sort	Liliya A. Mogylnytska
title	Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.
title_short	Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.
title_full	Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.
title_fullStr	Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.
title_full_unstemmed	Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.
title_sort	serum levels of endothelial monocyte activating polypeptide-ii in type 1 diabetes patients with microangyopathy and arterial hypertention.
publisher	Endocrinology Research Centre
publishDate	2016
url	https://doaj.org/article/f02c5b841db24e72815ed8a6e4d772b2
work_keys_str_mv	AT liliyaamogylnytska serumlevelsofendothelialmonocyteactivatingpolypeptideiiintype1diabetespatientswithmicroangyopathyandarterialhypertention AT borisnmankovsky serumlevelsofendothelialmonocyteactivatingpolypeptideiiintype1diabetespatientswithmicroangyopathyandarterialhypertention
_version_	1718429564322971648

Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.

Ejemplares similares